Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Reyka G. Jayasinghe, George Mulligan, April Cook, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn J. Cho, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 7090–7091.

https://doi.org/10.1182/blood-2022-167462

Published: 2022

Journal Articles

In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Zarko Manojlovic, PhD, Austin Christofferson, Christophe Legendre, PhD, Gill Spreyer, PhD, Seungchan Kim, PhD, Winnie Liang, PhD, George Mulligan, PhD, Pamela G. Kidd, MD, Scott Jewell, PhD, Mary Derome, MS, Jen Troups, Daniel Auclair, PhD, Sagar Lonial, MD, David Craig, PhD, Jonathan J Keats, PhD, John David Carpten, PhD

Blood (2015) 126 (23): 2973.

https://doi.org/10.1182/blood.V126.23.2973.2973

Published: 2015

Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Blood (2015) 126 (23): 811.

https://doi.org/10.1182/blood.V126.23.811.811

Published: 2015

Journal Articles

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Isabel JF Hofman, Mark van Duin, PhD, George Mulligan, PhD, Ellen Geerdens, Emanuela Garelli, Cecilia Mancini, Heidi Lemmens, Michel Delforge, Peter Vandenberghe, MDPhD, Iwona Wlodarska, Anna Aspesi, Lucienne Michaux, Pieter Sonneveld, MD PhD, Kim De Keersmaecker

Blood (2015) 126 (23): 2969.

https://doi.org/10.1182/blood.V126.23.2969.2969

Published: 2015

Journal Articles

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Rowan Kuiper, Mark van Duin, Martin H. van Vliet, Annemiek Broijl, Bronno van der Holt, Laila el Jarari, Erik H. van Beers, George Mulligan, Hervé Avet-Loiseau, Walter M. Gregory, Gareth Morgan, Hartmut Goldschmidt, Henk M. Lokhorst, Pieter Sonneveld

Blood (2015) 126 (17): 1996–2004.

https://doi.org/10.1182/blood-2015-05-644039

Published: 2015

Includes: Supplemental data

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Blood (2014) 123 (5): 632–639.

https://doi.org/10.1182/blood-2013-05-504340

Published: 2014

Includes: Supplemental data

Journal Articles

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, PhD, Gareth J Morgan, MD PhD, Hartmut Goldschmidt, MD, Uta Bertsch, MD, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3092.

https://doi.org/10.1182/blood.V122.21.3092.3092

Published: 2013

Journal Articles

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood (2012) 120 (23): 4513–4516.

https://doi.org/10.1182/blood-2012-05-426924

Published: 2012

Includes: Supplemental data

Journal Articles

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar

Blood (2012) 119 (19): 4375–4382.

https://doi.org/10.1182/blood-2011-11-395749

Published: 2012

Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Blood (2011) 118 (21): 265.

https://doi.org/10.1182/blood.V118.21.265.265

Published: 2011

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

Journal Articles

A High-Risk Survival Classifier for Multiple Myeloma

Rowan Kuiper, BSc, Annemiek Broyl, MD, Yvonne de Knegt, BSc, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Bronno van der Holt, PhD, Laila el Jarari, MSc, George Mulligan, PhD, Gareth Morgan, MD, Walter M Gregory, PhD, Hartmut Goldschmidt, MD, Henk M. Lokhorst, MD, Mark van Duin, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 1800.

https://doi.org/10.1182/blood.V118.21.1800.1800

Published: 2011

Journal Articles

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Kevin Doner, MD, Ian W. Flinn, MD, PhD, Brian K. Ulrich, MD, Stephen J. Noga, MD, PhD, Naveed M. Chowhan, MD, Steven W. Papish, MD, Tallat Mahmood, MD, James A Reeves, MD, Nicholas J. Di Bella, MD, Gerald J. Robbins, MD, Radhakrishnan Ramchandren, MD, Sein Aung, MD, William Lawler, MD, Sudha Parasuraman, MD, Maria M. Corvez, BA, George Mulligan, PhD, John P. Leonard, MD

Blood (2010) 116 (21): 1792.

https://doi.org/10.1182/blood.V116.21.1792.1792

Published: 2010

Journal Articles

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Shaji Kumar, MD, Ian W. Flinn, MD, PhD, Paul G Richardson, MD, Parameswaran Hari, MD, Natalie Scott Callander, MD, Stephen J. Noga, MD, PhD, A. Keith Stewart, MD, Jonathan Glass, MD, FACP, Robert M. Rifkin, MD, Jeffrey L Wolf, MD, Jose Estevam, BS, George Mulligan, PhD, Hongliang Shi, MS, Iain J. Webb, MD, FRCPC, S. Vincent Rajkumar, MD

Blood (2010) 116 (21): 621.

https://doi.org/10.1182/blood.V116.21.621.621

Published: 2010

Journal Articles

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Annemiek Broyl, MD, Rowan Kuiper, Martin H. van Vliet, PhD, Erik H. van Beers, PhD, Yvonne de Knegt, Bronno van der Holt, PhD, Laila el Jarari, Berna Beverloo, PhD, H. Lokhorst, Sonja Zweegman, George Mulligan, PhD, Hartmut Goldschmidt, Mark van Duin, PhD, Pieter Sonneveld

Blood (2010) 116 (21): 445.

https://doi.org/10.1182/blood.V116.21.445.445

Published: 2010

Journal Articles

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

Annemiek Broyl, Dirk Hose, Henk Lokhorst, Yvonne de Knegt, Justine Peeters, Anna Jauch, Uta Bertsch, Arjan Buijs, Marian Stevens-Kroef, H. Berna Beverloo, Edo Vellenga, Sonja Zweegman, Marie-Josée Kersten, Bronno van der Holt, Laila el Jarari, George Mulligan, Hartmut Goldschmidt, Mark van Duin, Pieter Sonneveld

Blood (2010) 116 (14): 2543–2553.

https://doi.org/10.1182/blood-2009-12-261032

Published: 2010

Includes: Supplemental data

NARROW

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

A High-Risk Survival Classifier for Multiple Myeloma

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only